| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.03 | 0.5 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.026 | 0.6 |